MustGrow Biologics Corp.

As of June 30, 2026, MustGrow Biologics Corporation carries a market capitalization of 19.29M, placing it among publicly traded companies globally. Its enterprise value stands at 16.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MustGrow Biologics Corporation's next confirmed earnings release is scheduled for December 1, 2026.

As of June 30, 2026, MustGrow Biologics Corporation has 70.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.28, and the price-to-book ratio stands at 5.42.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 16.57M versus a market cap of 19.29M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MustGrow Biologics Corporation maintains a current ratio of 3.63, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.21, indicating elevated leverage, while an interest coverage ratio of -79.89 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -86.81, reflecting losses generated across the asset base. The company generates approximately 290,198.98 in revenue per employee across its workforce of 7.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.36 indicates how many times MustGrow Biologics Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, MustGrow Biologics Corporation's stock has declined approximately 44.31% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.42.

Over the twelve months ended June 30, 2026, MustGrow Biologics Corporation generated 2.25M in revenue and converted that into -3.92M in net income, yielding earnings per share of -0.06. EBITDA reached -2.96M, while operating income came in at -2.98M.

As of June 30, 2026, MustGrow Biologics Corporation holds 3.08M in cash and equivalents against 363,282.39 in total debt, resulting in a net debt position of -2.72M. Total book value stands at 3.56M, with working capital of 3.66M providing operational flexibility.

MustGrow Biologics Corporation produced -2.01M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -2.01M - equivalent to -0.03 per share.

Over the twelve months ended June 30, 2026, MustGrow Biologics Corporation posted a gross margin of 48.61, reflecting its pricing power and cost economics. The operating margin of -132.57 and net profit margin of -174.40 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.17, meaning MustGrow Biologics Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, MustGrow Biologics Corporation has an Altman Z-Score of 0.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.